相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.
Article
Biochemistry & Molecular Biology
Kun Xu et al.
Summary: A chimeric RBD-dimer vaccine approach was developed to adapt to SARS-CoV-2 variants, providing broader neutralization and better protection against different strains in animal models. This approach is applicable for rapid immunogen updating and could be used to combat circulating and emerging SARS-CoV-2 variants.
News Item
Biotechnology & Applied Microbiology
Elie Dolgin
Summary: Numerous 'universal' coronavirus vaccines are currently in development, but the ability of new technology platforms to overcome immunological unknowns remains uncertain.
NATURE REVIEWS DRUG DISCOVERY
(2022)
Review
Immunology
Jianyang Liu et al.
Summary: To effectively control and prevent the COVID-19 pandemic, suitable vaccines have been rapidly researched and developed. However, the emergence of highly transmissible variants and their ability to escape vaccine-generated immune responses pose challenges to vaccine effectiveness. Evaluating the efficiency of new COVID-19 vaccines based on different technology platforms is necessary, but selecting suitable populations for clinical trials is challenging. Establishing surrogate endpoints based on neutralizing antibody titers could facilitate vaccine research and development.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Lydia Riepler et al.
Summary: Neutralizing antibodies are crucial for protection against viruses like SARS-CoV-2. This study compared four different assays for detecting these antibodies and found that they were all robust and yielded comparable results, indicating their reliability.
Editorial Material
Oncology
Shan Su et al.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Shuo Feng et al.
Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.
Editorial Material
Medicine, General & Internal
Youchun Wang
Article
Medicine, Research & Experimental
Jo-Lewis Banga Ndzouboukou et al.
Summary: Neutralizing antibody assays are crucial in managing the COVID-19 pandemic, aiding in protection assessment, donor screening, therapy testing, and vaccine efficacy prediction. This review compares different detection methods to enhance their clinical application.
CURRENT MEDICAL SCIENCE
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Biochemical Research Methods
Kevin R. Bewley et al.
Summary: The protocol from Public Health England discusses the use of three assays to measure neutralizing antibodies against SARS-CoV-2 for assessing COVID-19 vaccine efficacy. The PRNT is considered the gold standard for measuring levels of neutralizing antibodies, while the MNA and PNA offer advantages in terms of assay time, throughput, and operator workload. These assays have been critical in the development and licensure of COVID-19 vaccines and are important for demonstrating bioequivalence of future vaccines.
Article
Immunology
Lidong Guan et al.
Summary: By establishing and approving the first Chinese National Standard for SARS-CoV-2 neutralizing antibody, the quality and efficacy assessment of COVID-19 vaccines and therapeutics in China has been standardized and improved.
Editorial Material
Medicine, General & Internal
Nicole Lurie et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Immunology
Jianhui Nie et al.
EMERGING MICROBES & INFECTIONS
(2020)
Article
Immunology
Yan-Ping Li et al.
